Header Logo

Connection

MICHELLE A FANALE to Maytansine

Back to Details
This is a "connection" page, showing publications MICHELLE A FANALE has written about Maytansine.
MICHELLE A FANALE
Connection Strength
0.101
Maytansine
  1. Phase I multidose-escalation study of the anti-CD19 maytansinoid immunoconjugate SAR3419 administered by intravenous infusion every 3 weeks to patients with relapsed/refractory B-cell lymphoma. J Clin Oncol. 2012 Aug 01; 30(22):2776-82.
    View in: PubMed
    Score: 0.101
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.